What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alzheimer Disease
- Main trialPhase 1
- “BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the BDNF/TRKβ and microglia-mediated IL-33/OPN signaling pathways; therefore, it is expected to be a promising new drug that can significantly improve symptoms associated with Alzheimer's disease, including memory loss.”In the company’s words, NCT06535308 on ClinicalTrials.gov
Other drugs for Alzheimer Disease
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Apr 2026 | BnH-015B Clinical Trial in Moderate Alzheimer's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026